In a recent SEC filing, Becton Dickinson & Co (NYSE:BDX), a leading medical technology company, announced the outcomes of its 2025 Annual Meeting held on Monday. Shareholders voted on several key ...

Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday, months after ...

Shares of Becton, Dickinson and Company (NYSE:BDX – Get Free Report) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $249.08 which represents a slight increase of $0.38 or 0.15% from the prior close of $248.7. The stock opened at $248.68 and ...

This was the stock's third consecutive day of gains.

Learn more about whether Becton, Dickinson and Company or Intuitive Surgical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $243.45 which represents a slight increase of $2.98 or 1.24% from the prior close of $240.47. The stock opened at $239 and ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) was the recipient of some unusual options trading on Monday.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science ...

Goldman Sachs analyst Matthew Sykes double downgraded Cytek Biosciences (CTKB) to Sell from Buy with a price target of $4.50, down from $7. The ...

Becton, Dickinson and Company announced it repurchased $750M in BD stock to date in FY25. In addition, the board has authorized the company to ...